Skip to content
2000
Volume 19, Issue 2
  • ISSN: 2772-2708
  • E-ISSN: 2772-2716

Abstract

Background

The Coronavirus disease 2019 (COVID-19) pandemic, prompted by SARS-CoV-2, has created complicated health crises. An excessive inflammatory response and cytokine storm characterize severe COVID-19. Corticosteroids like dexamethasone and methylprednisolone are used for their anti-inflammatory effects, but comparisons of their efficacy are lacking.

Objective

This study seeks to rigorously assess and contrast the effectiveness of dexamethasone and methylprednisolone in combating COVID-19 infections.

Methods

This retrospective clinical study evaluates the effects of these two corticosteroids by reviewing the files of 500 hospitalized COVID-19 patients. The baseline characteristics of the patients, chest CT severity score, type of steroid prescription, duration of hospitalization and steroid prescription, dosage of corticosteroid therapy, their recovery status, hospital mortality, and specific disease severity-associated markers, such as lactate dehydrogenase (LDH), complete blood count (CBC), C-reactive protein (CRP), and Erythrocyte sedimentation rate (ESR) were collected and compared.

Results

The study found no significant difference in most disease severity-associated markers between the two corticosteroid groups. However, lower mortality rates and shortened hospital stays were significantly associated with dexamethasone, especially in critical patient groups. A detailed analysis of inflammatory markers suggested minimal differences based on the type of corticosteroid used.

Conclusion

The study indicates that dexamethasone may have some advantages in specific clinical outcomes. Further research needs to explore the mechanisms involved despite similar anti-inflammatory profiles.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raiad/10.2174/0127722708310247240718100251
2024-07-26
2025-10-22

  • From This Site

    /content/journals/raiad/10.2174/0127722708310247240718100251
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Eurosurveillance editorial teamNote from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern.Euro Surveill.2020255200131e
     [Google Scholar]
  2. World Health OrganizationWHO announces COVID-19 outbreak a pandemic.2020
  3. World Health OrganizationStatement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).2020Available From: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
  4. World Health OrganizationClinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: Interim guidance.2019Available From: https://www.who.int/publications/i/item/WHO-MERS-Clinical-15-1-Revision-1
  5. World Health OrganizationCOVID-19 weekly epidemiological update, edition 134, 16 March 2023.2023Available From: https://iris.who.int/handle/10665/366534
  6. SabetianG. MoghadamiM. Hashemizadeh Fard HaghighiL. ShahriariradR. FallahiM.J. AsmarianN. MoeiniY.S. COVID-19 infection among healthcare workers: A cross-sectional study in southwest Iran.Virol. J.20211815810.1186/s12985‑021‑01532‑033731169
     [Google Scholar]
  7. LotfiM SefidbakhtS MoghadamiM IranpourP EmamiY JafariSH Introduction of a radiologic severity index for the 2019 Novel Corona Virus (COVID-19).Preprint2020
     [Google Scholar]
  8. ShahriariradR. SarkariB. COVID-19: Clinical or laboratory diagnosis? A matter of debate.Trop. Doct.202151113113210.1177/004947552094544632762302
     [Google Scholar]
  9. AshrafM.A. KeshavarzP. HosseinpourP. ErfaniA. RoshanshadA. PourdastA. Nowrouzi-SohrabiP. ChaichianS. PoordastT. Coronavirus disease 2019 (COVID-19): A systematic review of pregnancy and the possibility of vertical transmission.J. Reprod. Infertil.202021315716832685412
     [Google Scholar]
  10. MirahmadizadehA. RanjbarK. ShahriariradR. ErfaniA. GhaemH. JafariK. RahimiT. Evaluation of students’ attitude and emotions towards the sudden closure of schools during the COVID-19 pandemic: A cross-sectional study.BMC Psychol.20208113410.1186/s40359‑020‑00500‑733334376
     [Google Scholar]
  11. ShahriariradR. ErfaniA. RanjbarK. BazrafshanA. MirahmadizadehA. The mental health impact of COVID-19 outbreak: A Nationwide Survey in Iran.Int. J. Ment. Health Syst.20211511910.1186/s13033‑021‑00445‑333640006
     [Google Scholar]
  12. ErfaniA. ShahriariradR. RanjbarK. MirahmadizadehA. MoghadamiM. Knowledge, attitude, and practice toward the novel coronavirus (COVID-19) outbreak: A population-based survey in Iran.J Health Sci Surveill Syst.2023113Suppl.578591
     [Google Scholar]
  13. HuangC. WangY. LiX. RenL. ZhaoJ. HuY. ZhangL. FanG. XuJ. GuX. ChengZ. YuT. XiaJ. WeiY. WuW. XieX. YinW. LiH. LiuM. XiaoY. GaoH. GuoL. XieJ. WangG. JiangR. GaoZ. JinQ. WangJ. CaoB. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet20203951022349750610.1016/S0140‑6736(20)30183‑531986264
     [Google Scholar]
  14. WiersingaW.J. RhodesA. ChengA.C. PeacockS.J. PrescottH.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review.JAMA2020324878279310.1001/jama.2020.1283932648899
     [Google Scholar]
  15. TayM.Z. PohC.M. RéniaL. MacAryP.A. NgL.F.P. The trinity of COVID-19: Immunity, inflammation and intervention.Nat. Rev. Immunol.202020636337410.1038/s41577‑020‑0311‑832346093
     [Google Scholar]
  16. GuanW. NiZ. HuY. LiangW. OuC. HeJ. LiuL. ShanH. LeiC. HuiD.S.C. DuB. LiL. ZengG. YuenK.Y. ChenR. TangC. WangT. ChenP. XiangJ. LiS. WangJ. LiangZ. PengY. WeiL. LiuY. HuY. PengP. WangJ. LiuJ. ChenZ. LiG. ZhengZ. QiuS. LuoJ. YeC. ZhuS. ZhongN. Clinical characteristics of coronavirus disease 2019 in China.N. Engl. J. Med.2020382181708172010.1056/NEJMoa200203232109013
     [Google Scholar]
  17. WangD HuB HuC ZhuF LiuX ZhangJ Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China.Jama20203231110619
     [Google Scholar]
  18. MagroG. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc.Cytokine X20202210002910.1016/j.cytox.2020.10002932421092
     [Google Scholar]
  19. ZhangC. WuZ. LiJ.W. ZhaoH. WangG.Q. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.Int. J. Antimicrob. Agents202055510595410.1016/j.ijantimicag.2020.10595432234467
     [Google Scholar]
  20. Prokunina-OlssonL. AlphonseN. DickensonR.E. DurbinJ.E. GlennJ.S. HartmannR. KotenkoS.V. LazearH.M. O’BrienT.R. OdendallC. OnabajoO.O. PiontkivskaH. SanterD.M. ReichN.C. WackA. ZanoniI. COVID-19 and emerging viral infections: The case for interferon lambda.J. Exp. Med.20202175e2020065310.1084/jem.2020065332289152
     [Google Scholar]
  21. RitchieA.I. SinganayagamA. Immunosuppression for hyperinflammation in COVID-19: A double-edged sword?Lancet202039510230111110.1016/S0140‑6736(20)30691‑732220278
     [Google Scholar]
  22. FeldmannM. MainiR.N. WoodyJ.N. HolgateS.T. WinterG. RowlandM. RichardsD. HussellT. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.Lancet2020395102341407140910.1016/S0140‑6736(20)30858‑832278362
     [Google Scholar]
  23. AngelopoulouA. AlexandrisN. KonstantinouE. MesiakarisK. ZanidisC. FarsalinosK. PoulasK. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.Environ. Res.202018810985810.1016/j.envres.2020.10985832846644
     [Google Scholar]
  24. GolonkaR.M. SahaP. YeohB.S. ChattopadhyayS. GewirtzA.T. JoeB. Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.Physiol Genomics.2020525217221
     [Google Scholar]
  25. De BiasiS. MeschiariM. GibelliniL. BellinazziC. BorellaR. FidanzaL. GozziL. IannoneA. Lo TartaroD. MattioliM. PaoliniA. MenozziM. MilićJ. FranceschiG. FantiniR. TonelliR. SitaM. SartiM. TrentiT. BrugioniL. CicchettiL. FacchinettiF. PietrangeloA. CliniE. GirardisM. GuaraldiG. MussiniC. CossarizzaA. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.Nat. Commun.2020111343410.1038/s41467‑020‑17292‑432632085
     [Google Scholar]
  26. BagcaB.G. AvciC.B. Overview of the COVID-19 and JAK/STAT pathway inhibition: Ruxolitinib perspective.Cytokine Growth Factor Rev.202054516110.1016/j.cytogfr.2020.06.013
     [Google Scholar]
  27. LuoW. LiY.X. JiangL.J. ChenQ. WangT. YeD.W. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19.Trends Pharmacol. Sci.202041853154310.1016/j.tips.2020.06.00732580895
     [Google Scholar]
  28. KõksG. UudeleppM.L. LimbachM. PetersonP. ReimannE. KõksS. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies.Am. J. Pathol.2015185112898290610.1016/j.ajpath.2015.07.00626348578
     [Google Scholar]
  29. OkamotoY. ShikanoS. Emerging roles of a chemoattractant receptor GPR15 and ligands in pathophysiology.Front. Immunol.202314117945610.3389/fimmu.2023.117945637457732
     [Google Scholar]
  30. YeQ. WangB. MaoJ. Cytokine storm in COVID-19 and treatment.J. Infect.202080660761310.1016/j.jinf.2020.03.03732283152
     [Google Scholar]
  31. ChoudharyS. SharmaK. SilakariO. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.Microb. Pathog.202115010467310.1016/j.micpath.2020.10467333278517
     [Google Scholar]
  32. KumarM. Al KhodorS. Pathophysiology and treatment strategies for COVID-19.J. Transl. Med.202018135310.1186/s12967‑020‑02520‑832933536
     [Google Scholar]
  33. HorbyP. LimW.S. EmbersonJ.R. MafhamM. BellJ.L. LinsellL. StaplinN. BrightlingC. UstianowskiA. ElmahiE. PrudonB. GreenC. FeltonT. ChadwickD. RegeK. FeganC. ChappellL.C. FaustS.N. JakiT. JefferyK. MontgomeryA. RowanK. JuszczakE. BaillieJ.K. HaynesR. LandrayM.J. Dexamethasone in Hospitalized Patients with Covid-19.N. Engl. J. Med.2021384869370410.1056/NEJMoa202143632678530
     [Google Scholar]
  34. StrehlC. EhlersL. GaberT. ButtgereitF. Glucocorticoids—all-rounders tackling the versatile players of the immune system.Front. Immunol.201910174410.3389/fimmu.2019.0174431396235
     [Google Scholar]
  35. MehtaJ. RoltaR. MehtaB.B. KaushikN. ChoiE.H. KaushikN.K. Role of dexamethasone and methylprednisolone corticosteroids in coronavirus disease 2019 hospitalized patients: A Review.Front. Microbiol.20221381335810.3389/fmicb.2022.81335835242118
     [Google Scholar]
  36. ScheinmanR.I. CogswellP.C. LofquistA.K. BaldwinA.S.Jr Role of transcriptional activation of I κ B α in mediation of immunosuppression by glucocorticoids.Science1995270523428328610.1126/science.270.5234.2837569975
     [Google Scholar]
  37. Jaime-PérezJ.C. Rodríguez-MartínezM. Gómez-de-LeónA. Tarín-ArzagaL. Gómez-AlmaguerD. Current approaches for the treatment of autoimmune hemolytic anemia.Arch. Immunol. Ther. Exp. (Warsz.)201361538539510.1007/s00005‑013‑0232‑323689532
     [Google Scholar]
  38. EdalatifardM. AkhtariM. SalehiM. NaderiZ. JamshidiA. MostafaeiS. NajafizadehS.R. FarhadiE. JaliliN. EsfahaniM. RahimiB. KazemzadehH. Mahmoodi AliabadiM. GhazanfariT. SattarianM. Ebrahimi LouyehH. RaeeskaramiS.R. JamalimoghadamsiahkaliS. KhajaviradN. MahmoudiM. RostamianA. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial.Eur. Respir. J.2020566200280810.1183/13993003.02808‑202032943404
     [Google Scholar]
  39. SterneJ.A.C. MurthyS. DiazJ.V. SlutskyA.S. VillarJ. AngusD.C. AnnaneD. AzevedoL.C.P. BerwangerO. CavalcantiA.B. DequinP.F. DuB. EmbersonJ. FisherD. GiraudeauB. GordonA.C. GranholmA. GreenC. HaynesR. HemingN. HigginsJ.P.T. HorbyP. JüniP. LandrayM.J. Le GougeA. LeclercM. LimW.S. MachadoF.R. McArthurC. MezianiF. MøllerM.H. PernerA. PetersenM.W. SavovicJ. TomaziniB. VeigaV.C. WebbS. MarshallJ.C. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19.JAMA2020324131330134110.1001/jama.2020.1702332876694
     [Google Scholar]
  40. SiemieniukRA BartoszkoJJ ZeraatkarD KumE QasimA MartinezJPD Drug treatments for covid-19: Living systematic review and network meta-analysis.BMJ20202020370
     [Google Scholar]
  41. GroupC.H. WagnerC. GrieselM. MikolajewskaA. MuellerA. NothackerM. Systemic corticosteroids for the treatment of COVID-19.Cochrane Database Syst. Rev.199620218
     [Google Scholar]
  42. HamedD.M. BelhoulK.M. Al MaazmiN.A. GhayoorF. MoinM. Al SuwaidiM. NarainenM. MakkiM. AbdulRahmanM. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison.J. Infect. Public Health202114898598910.1016/j.jiph.2021.06.00334153729
     [Google Scholar]
  43. HongS. WangH. ZhangZ. QiaoL. The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis.Steroids202218310902210.1016/j.steroids.2022.10902235346661
     [Google Scholar]
  44. FatimaS.A. AsifM. KhanK.A. SiddiqueN. KhanA.Z. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.Ann. Med. Surg. (Lond.)20206041341610.1016/j.amsu.2020.11.02733200031
     [Google Scholar]
  45. RanaM.A. HashmiM.S. QayyumA. PervaizR. SaleemM. MunirM.F. Ullah SaifM.M. Comparison of efficacy of dexamethasone and methylprednisolone in improving PaO2/FiO2 ratio among COVID-19 patients.Cureus20201210e1091810.7759/cureus.1091833194485
     [Google Scholar]
  46. AslamJ. MasroorM. AhmadS. HussainW. MansoorH. KhanL. Efficacy of methylprednisolone with dexamethasone in patients with severe Covid pneumonia in term of clinical and biochemical improvement.Pak. J. Med. Health Sci.2021151026352636
     [Google Scholar]
  47. BusoR. CinettoF. Dell’EderaA. VeneranN. FacchiniC. BiscaroV. SchiavonS. VianE. GrossiU. ZanusG. GiobbiaM. ScarpaR. AgostiniC. RattazziM. FeliceC. Comparison between dexamethasone and methylprednisolone therapy in patients with COVID-19 pneumonia admitted to non-intensive medical units.J. Clin. Med.20211024581210.3390/jcm1024581234945108
     [Google Scholar]
  48. Du PlessisE.M. LallaU. AllwoodB.W. LouwE.H. NortjeA. ParkerA. TaljaardJ.J. AyeleB.T. NyasuluP.S. KoegelenbergC.F.N. Corticosteroids in critical COVID-19: Are all corticosteroids equal?S. Afr. Med. J.2021111655055334382564
     [Google Scholar]
  49. El mezzeouiS. El aidouniG. MerbouhM. El KaouiniA. AftissF.Z. berrichiS. BerrajaaS. BkiyerH. AbdaN. HousniB. Dexamethasone or methylprednisolone therapy in covid-19 pneumonia: A retrospective and comparative study of 513 cases.Ann. Med. Surg. (Lond.)20217010285810.1016/j.amsu.2021.10285834545308
     [Google Scholar]
  50. KoJ.J. WuC. MehtaN. Wald-DicklerN. YangW. QiaoR. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19.J. Intensive Care Med.202136667368010.1177/088506662199405733632000
     [Google Scholar]
  51. Mora-LujánJ.M. TuellsM. MonteroA. FormigaF. HomsN.A. Albà-AlbalateJ. CorbellaX. Rubio-RivasM. High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: A retrospective propensity score matched analysis.J. Clin. Med.20211019446510.3390/jcm1019446534640481
     [Google Scholar]
  52. PinzónM.A. OrtizS. HolguínH. BetancurJ.F. Cardona ArangoD. LaniadoH. Arias AriasC. MuñozB. QuicenoJ. JaramilloD. RamirezZ. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.PLoS One2021165e025205710.1371/journal.pone.025205734033648
     [Google Scholar]
  53. RanjbarK. MoghadamiM. MirahmadizadehA. FallahiM.J. KhalooV. ShahriariradR. ErfaniA. KhodamoradiZ. Gholampoor SaadiM.H. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial.BMC Infect. Dis.202121133710.1186/s12879‑021‑06045‑3
     [Google Scholar]
  54. SaeedM.A.M. MohamedA.H. OwaynatA.H. Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients.Egypt. J. Intern. Med.20223411910.1186/s43162‑022‑00113‑z35194371
     [Google Scholar]
  55. SolimanO.M. MoeenS.M. AbbasY.A. KamelE.Z. The impact of dexamethasone versus methylprednisolone upon neutrophil/lymphocyte ratio in COVID-19 patients admitted to ICU and its implication upon mortality.Egypt. J. Anaesth.2022381788410.1080/11101849.2021.2024985
     [Google Scholar]
  56. RagabD. Salah EldinH. TaeimahM. KhattabR. SalemR. The COVID-19 cytokine storm; what we know so far.Front. Immunol.202011144610.3389/fimmu.2020.0144632612617
     [Google Scholar]
  57. Iran’s National Guideline for2019Available From: https://irimc.org/Portals/0/Images/News/%20%20%20%20%20%20-19.pdf
  58. WHOCorticosteroids for COVID-19: Living guidance, 2 September 20202020Available From: https://iris.who.int/handle/10665/334125
  59. SharmaS. AggarwalA. SharmaR. PatrasE. SinghalA. Correlation of chest CT severity score with clinical parameters in COVID-19 pulmonary disease in a tertiary care hospital in Delhi during the pandemic period.Egypt. J. Radiol. Nucl. Med.202253
     [Google Scholar]
  60. ZhouS. ChenC. HuY. LvW. AiT. XiaL. Chest CT imaging features and severity scores as biomarkers for prognostic prediction in patients with COVID-19.Ann. Transl. Med.2020821144910.21037/atm‑20‑342133313194
     [Google Scholar]
  61. SterneJ.A.C. MurthyS. DiazJ.V. SlutskyA.S. VillarJ. AngusD.C. AnnaneD. AzevedoL.C.P. BerwangerO. CavalcantiA.B. DequinP.F. DuB. EmbersonJ. FisherD. GiraudeauB. GordonA.C. GranholmA. GreenC. HaynesR. HemingN. HigginsJ.P.T. HorbyP. JüniP. LandrayM.J. Le GougeA. LeclercM. LimW.S. MachadoF.R. McArthurC. MezianiF. MøllerM.H. PernerA. PetersenM.W. SavovicJ. TomaziniB. VeigaV.C. WebbS. MarshallJ.C. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis.JAMA2020324131330134110.1001/jama.2020.1702332876694
     [Google Scholar]
  62. RussellC.D. MillarJ.E. BaillieJ.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.Lancet20203951022347347510.1016/S0140‑6736(20)30317‑232043983
     [Google Scholar]
  63. van PaassenJ. VosJ.S. HoekstraE.M. NeumannK.M.I. BootP.C. ArbousS.M. Corticosteroid use in COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.Crit. Care202024169610.1186/s13054‑020‑03400‑933317589
     [Google Scholar]
  64. WHOCorticosteroids for COVID-19.2020Available From: https://iris.who.int/bitstream/handle/10665/334125/WHO-2019-nCoV-Corticosteroids-2020.1-eng.pdf?sequence=1
  65. DraghiciS. NguyenT.M. SonnaL.A. ZiraldoC. VanciuR. FadelR. MorrisonA. KenneyR.M. AlangadenG. RameshM. MorG. COVID-19: Disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases.Bioinformatics202137172691269810.1093/bioinformatics/btab16333693506
     [Google Scholar]
  66. VillarJ. FerrandoC. MartínezD. AmbrósA. MuñozT. SolerJ.A. AguilarG. AlbaF. González-HiguerasE. ConesaL.A. Martín-RodríguezC. Díaz-DomínguezF.J. Serna-GrandeP. RivasR. FerreresJ. BeldaJ. CapillaL. TalletA. AñónJ.M. FernándezR.L. González-MartínJ.M. AguilarG. AlbaF. ÁlvarezJ. AmbrósA. AñónJ.M. AsensioM.J. BeldaJ. BlancoJ. BlascoM. CachafeiroL. del CampoR. CapillaL. CarbonellJ.A. CarbonellN. CariñenaA. CarriedoD. ChicoM. ConesaL.A. CorpasR. CuervoJ. Díaz-DomínguezF.J. Domínguez-AnteloC. FernándezL. FernándezR.L. FerrandoC. FerreresJ. GamboaE. González-HiguerasE. González-LuengoR.I. González-MartínJ.M. MartínezD. Martín-RodríguezC. MuñozT. Ortiz Díaz-MiguelR. Pérez-GonzálezR. PrietoA.M. PrietoI. RivasR. Rojas-VigueraL. RomeraM.A. Sánchez-BallesterosJ. SeguraJ.M. Serna-GrandeP. SerranoA. SolanoR. SolerJ.A. SoroM. TalletA. VillarJ. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial.Lancet Respir. Med.20208326727610.1016/S2213‑2600(19)30417‑532043986
     [Google Scholar]
  67. YangR. XiongY. KeH. ChenT. GaoS. The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.Eur. J. Clin. Invest.20205011e1341210.1111/eci.1341232954492
     [Google Scholar]
  68. JamilZ. AlmajhdiF.N. KhalidS. AsgharM. AhmedJ. WaheedY. Comparison of low-versus high-dose steroids in the clinical outcome of hospitalized COVID-19 patients.Antibiotics (Basel)20211012151010.3390/antibiotics1012151034943722
     [Google Scholar]
  69. SariA. EkinciO. SaraçoğluK.T. BalıkR. AslanM. BalıkY. ÖnalC. AslanM. CevherS. ParmaksızA. VatanseverŞ. ÇicekM.C. AyanÖ.S. Şensöz ÇelikG. ToprakA. YılmazM. YurtE. BakanN. TekinS. AdıyekeE. A comparison of the effects of dexamethasone and methylprednisolone, used on level-3 intensive care COVID-19 patients, on mortality: A Multi-Center Retrospective Study.J. Korean Med. Sci.20233829e23210.3346/jkms.2023.38.e23237489719
     [Google Scholar]
  70. WuC. ChenX. CaiY. XiaJ. ZhouX. XuS. HuangH. ZhangL. ZhouX. DuC. ZhangY. SongJ. WangS. ChaoY. YangZ. XuJ. ZhouX. ChenD. XiongW. XuL. ZhouF. JiangJ. BaiC. ZhengJ. SongY. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.JAMA Intern. Med.2020180793494310.1001/jamainternmed.2020.099432167524
     [Google Scholar]
  71. HongS. WangH. LiS. LiuJ. QiaoL. A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: Methylprednisolone versus dexamethasone.BMC Infect. Dis.202323129010.1186/s12879‑023‑08280‑237147596
     [Google Scholar]
  72. WatanabeY. NakamuraI. SatoS. FujitaH. KobayashiT. WatanabeH. Comparison of methylprednisolone pulse vs conventional dexamethasone for adult cases of COVID-19 requiring oxygen; a Japanese retrospective cohort study.J. Infect. Chemother.202329326927310.1016/j.jiac.2022.11.00836436740
     [Google Scholar]
  73. Approved Drug ProductsF.D.A. Hemady dexamethasone oral tablets.2019Available From: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf
  74. SzeflerS.J. EblingW.F. GeorgitisJ.W. JuskoW.J. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.Eur. J. Clin. Pharmacol.198630332332910.1007/BF005415373732369
     [Google Scholar]
  75. GargD.C. WagnerJ.G. SakmarE. WeidlerD.J. AlbertK.S. Rectal and oral absorption of methylprednisolone acetate.Clin. Pharmacol. Ther.197926223223910.1002/cpt1979262232455892
     [Google Scholar]
/content/journals/raiad/10.2174/0127722708310247240718100251
Loading
A Comparative Study of Dexamethasone and Methylprednisolone in COVID-19 Patients: Clinical Outcomes and Inflammatory Markers
Rec Adv Inflamm Allergy Drug Discov 19, 259 (2025); https://doi.org/10.2174/0127722708310247240718100251
/content/journals/raiad/10.2174/0127722708310247240718100251
/content/journals/raiad/10.2174/0127722708310247240718100251
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): COVID-19; Dexamethasone; disease; hospitalization; methylprednisolone; SARS-CoV-2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test